GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dr Reddy's Laboratories Ltd (NYSE:RDY) » Definitions » Other Income (Expense)

RDY (Dr Reddy's Laboratories) Other Income (Expense) : $62 Mil (TTM As of Sep. 2024)


View and export this data going back to 2001. Start your Free Trial

What is Dr Reddy's Laboratories Other Income (Expense)?

Dr Reddy's Laboratories's other income expense for the Dr Reddy's Laboratories's pretax income for the three months ended in Sep. 2024 was $14 Mil. Its other income expense for the trailing twelve months (TTM) ended in Sep. 2024 was $62 Mil.

Dr Reddy's Laboratories Other Income (Expense) Historical Data

The historical data trend for Dr Reddy's Laboratories's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dr Reddy's Laboratories Other Income (Expense) Chart

Dr Reddy's Laboratories Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Other Income (Expense)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -196.49 -87.24 -47.62 18.98 72.21

Dr Reddy's Laboratories Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Other Income (Expense) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.45 13.96 32.33 0.85 14.49

Dr Reddy's Laboratories Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $62 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dr Reddy's Laboratories  (NYSE:RDY) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Dr Reddy's Laboratories Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dr Reddy's Laboratories Ltd (NYSE:RDY) » Definitions » Other Income (Expense)
Comparable Companies
BOM:543904 BOM:532321 NSE:TORNTPHARM BOM:500257 NSE:AUROPHARMA NSE:ALKEM NSE:DIVISLAB BOM:532296 BOM:524494 BOM:532331 ZTS XTER:MRK NSE:SUNPHARMA LSE:HLN TSE:4502 XSWX:GALD XSWX:SDZ XTAE:TEVA VTRS HKSE:03692
Traded in Other Exchanges
DRREDDY:India 500124:India RDDA:Germany RDDA:Germany R1DY34:Brazil
Address
8-2-337, Road No. 3, Banjara Hills, Hyderabad, TG, IND, 500 034
Website
https://www.drreddys.com
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.